DrugDashboards

Integra F

Ferrous Fumarate and Polysacchride Iron Complex and Folic Acid · FERROUS FUMARATE 62.5 mg/1; FERROUS ASPARTO GLYCINATE 62.5 mg/1; FOLIC ACID 1 mg/1; ASCORBIC ACID 40 mg/1; NIACIN 3 mg/1 · Capsule · Oral · U.S. Pharmaceutical Corporation

NDC 52747-0711-30 · 30 CAPSULE in 1 BOTTLE, PLASTIC · UNAPPROVED DRUG OTHER · View full market →

The short version

Only one company currently supplies this market — there is no backup if it stumbles. The price is up 12% over the past year, to $0.5615 per unit. Put together: worth watching — several of the pressures that precede supply trouble are present at once.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

$0$0.2$0.4$0.6Oct 2013Sep 2026$0.5615
31 price points · per EASource: CMS NADAC

Estimated fill cost

#30 count
$16.84
#90 count
$50.53

Estimates: latest NADAC unit price × quantity. Pharmacy acquisition cost only — excludes dispensing fees, markup, and insurance terms.

Medicaid spend (2025)

$47,171
2,591 prescriptions paid by Medicaid nationally · all Medicaid spend →

Supply fragility

30Elevated risk

The score is counting real pressure here. One of these alone is routine; it’s the combination that makes this market worth watching.

  • 1 active manufacturer+30

The score counts pressure that is already visible — fewer makers, shortages, recalls, falling prices. 0 means none of it; 100 means all of it at once. Recomputed daily · as of Sep 3, 2026

90-day shortage risk (model v2)

0.0%chance of a new FDA shortage posting for ferrous fumarate and polysacchride iron complex and folic acid (oral solid) in the next 90 days

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
TE code
Approval date
Patents / exclusivity

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Ferrous Fumarate and Polysacchride Iron Complex and Folic Acid (Capsule)

LabelerStrengthFirst seenLast seen
U.S. Pharmaceutical CorporationFERROUS FUMARATE 62.5 mg/1; FERROUS ASPARTO GLYCINATE 62.5 mg/1; FOLIC ACID 1 mg/1; ASCORBIC ACID 40 mg/1; NIACIN 3 mg/1Aug 26, 2026Sep 2, 2026
U.S. Pharmaceutical CorporationFERROUS FUMARATE 40 mg/1; FERROUS ASPARTO GLYCINATE 62.5 mg/1; FOLIC ACID 62.5 mg/1; ASCORBIC ACID 1 mg/1; NIACIN 3 mg/1Jul 22, 2026Aug 19, 2026
U.S. Pharmaceutical CorporationASCORBIC ACID 40 mg/1; FERROUS ASPARTO GLYCINATE 62.5 mg/1; FERROUS FUMARATE 62.5 mg/1; FOLIC ACID 1 mg/1; NIACIN 3 mg/1Jul 15, 2026Jul 15, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Integra F — NDC 52747-0711-30," retrieved September 3, 2026, https://drugdashboards.com/drug/52747071130.

Free to cite with attribution — see how the data is put together.